Selective MyD88-dependent pathway inhibition by the cyanobacterial natural product malyngamide F acetate

In response to evolutionary selective pressure, prokaryotes have developed a rich array of secondary metabolites, some of which may be inhibitory to the innate immune system and the inflammatory response in vertebrates. We utilized the RAW264.7 macrophage cell line stimulated with LPS in a nitric ox...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of pharmacology Vol. 629; no. 1; pp. 140 - 146
Main Authors Villa, Francisco A., Lieske, Kelly, Gerwick, Lena
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 10.03.2010
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In response to evolutionary selective pressure, prokaryotes have developed a rich array of secondary metabolites, some of which may be inhibitory to the innate immune system and the inflammatory response in vertebrates. We utilized the RAW264.7 macrophage cell line stimulated with LPS in a nitric oxide (NO) assay to screen for compounds with immunomodulatory activities from a library of marine natural products, and found that the malyngamide structure class, found commonly in the marine cyanobacterium Lyngbya majuscula, has potent activity. Several of the malyngamides were found to possess IC50 values of 5.4–18 µM. Malyngamide F acetate exhibited strong concentration-dependent anti-inflammatory activity in the NO assay with an IC50 of 7.1 µM and with no cytotoxicity at the concentrations tested. Subsequent real-time PCR of selected genes revealed a unique cytokine profile after LPS stimulation (TLR4) with decreased expression of iNOS, IL-1β, IL-6, and IL-10, but increased TNF-α expression. Additional experiments utilizing CpG and Poly I:C stimulation to selectively activate the MyD88-dependent and -independent pathways via TLR9 and TLR3 substantiated the finding that malyngamide F acetate selectively inhibits the MyD88-dependent pathway. To our knowledge, this is the first report of a natural product inhibiting the MyD88-dependent pathway.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
fvilla@ucsd.edu, klieske@ucsd.edu, lgerwick@ucsd.edu
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2009.12.002